Onco-Innovations Limited
ONNVF
$0.46
-$0.01-2.49%
OTC PK
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | 15.97% | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | 15.97% | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | 74.07% | -- | -- | -- | |
| SG&A Expenses | 122.80% | -- | -- | -- | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 150.56% | -- | -- | -- | |
| Operating Income | -152.20% | -- | -- | -- | |
| Income Before Tax | -47.19% | -- | -- | -- | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -47.19% | -- | -- | -- | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -47.19% | -- | -- | -- | |
| EBIT | -152.20% | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | -19.02% | -- | -- | -- | |
| Normalized Basic EPS | -84.68% | -- | -- | -- | |
| EPS Diluted | -19.02% | -- | -- | -- | |
| Normalized Diluted EPS | -84.68% | -- | -- | -- | |
| Average Basic Shares Outstanding | 38.15% | -- | -- | -- | |
| Average Diluted Shares Outstanding | 38.15% | -- | -- | -- | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |